Metronidazole, a potent nitroimidazole derivative, remains a cornerstone of anti-infective therapy globally. As a World Health Organization (WHO) Essential Medicine, its demand spans from acute clinical settings to broad prophylactic surgical applications. The 500 Mg tablet formulation, in particular, represents the therapeutic gold standard for treating anaerobic bacterial infections and specific protozoal diseases.
Projected CAGR of 4.8% in the Nitroimidazole segment
In the current pharmaceutical landscape, procurement directors are shifting focus from mere price points to "Supply Chain Resilience" and "Analytical Transparency." Jiangxi Serum Pharma Industries Co., Ltd. addresses these systemic needs by integrating advanced manufacturing technologies with rigorous GMP compliance. Our Metronidazole 500 Mg tabs are not just products; they are mission-critical components of healthcare infrastructure.
Rising urbanization and healthcare access in emerging markets (APAC and LATAM) have catalyzed a 15% increase in demand for high-efficacy anti-infectives. Large-scale hospital tenders now mandate 99% purity levels and verified dissolution profiles.
We provide end-to-end solutions including stability testing under Zone IVb conditions, ensuring that Metronidazole 500 Mg maintains potency in tropical climates—a critical factor for international NGOs and relief agencies.
Our R&D is currently pioneering Co-Crystallization techniques to enhance the solubility and taste-masking of Metronidazole, facilitating better patient compliance in pediatric and geriatric demographics.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Established
Global Clients
Suppliers
Annual Sales
Metronidazole is rapidly and almost completely absorbed following oral administration. Our 500 Mg formulation is engineered with specialized excipients to achieve a T-max of 1–2 hours, ensuring rapid therapeutic onset for acute anaerobic infections. The high volume of distribution ensures effective penetration into bone, CSF, and abscess cavities.
As part of our commitment to sustainable chemistry, we are exploring bio-fermentation pathways for the synthesis of nitroimidazole intermediates. This reduces the carbon footprint by 30% compared to traditional chemical synthesis while maintaining BP/USP pharmacopeial standards.
The global pharmaceutical supply chain is currently undergoing a "Regionalization Phase." Manufacturers are expected to provide not just products, but localized regulatory support. Serum Pharma leverages its position in China's pharmaceutical hub to provide cost-effective yet high-compliance products to the world.
Integration of blockchain for batch traceability from API sourcing to final tablet packaging. This ensures complete transparency for global distributors and reduces the risk of counterfeit entries in the market.
We provide comprehensive Dossier support (CTD/eCTD format) for local MOH registrations in over 50 countries, significantly shortening the "Time-to-Market" for our partners.
Our tablets are formulated for stability. They should be stored below 30°C in a dry place, protected from light. For tropical climates, we offer specialized Alu-Alu blister packaging to prevent degradation.
Yes, we offer comprehensive customization for Metronidazole 500 Mg, including tablet embossing, packaging design, and specific dosage variations to meet local market needs.
All batches strictly adhere to BP (British Pharmacopoeia) and USP (United States Pharmacopeia) standards, manufactured in GMP-certified facilities with full COA documentation.
We maintain strategic reserves of active pharmaceutical ingredients (APIs) and have long-term partnerships with leading logistics providers to ensure timely delivery even during global supply disruptions.
Deep dive into the transition from animal to plant-based sources in the nutritional sector.
Why this molecule remains essential for modern inflammatory treatment protocols.
FDA's rapid approval of oral GLP1 weight-loss drugs marks a new era in molecular entity speed-to-market.
Read Full Report →
